Exelixis EXEL
NASDAQ EXEL
$59.02 -0.11 (-0.19%)
As of: Sep 4, 2026 · 3:59 PM EDT

Exelixis (EXEL) Long-Term Deferred Tax (2018 - 2026)

Exelixis (EXEL) posted quarterly Long-Term Deferred Tax of $293.7 million for Q2 2026, down 29.9% year-over-year from $419.0 million in Q2 2025, and little changed quarter-over-quarter from $292.6 million in Q1 2026.

Analysis

Exelixis (EXEL) Long-Term Deferred Tax (2018 - 2026) Analysis & Trends

Exelixis' Long-Term Deferred Tax history runs 9 years deep, the most recent figure standing at $293.7 million for Q2 2026.

  • In Q2 2026, Long-Term Deferred Tax fell 29.9% year-over-year to $293.7 million; the TTM figure through Apr 2026 stood at $293.7 million (down 29.9% YoY), while the FY2026 annual figure was $292.6 million, down 30.34% from the prior year.
  • Long-Term Deferred Tax for Q2 2026 stood at $293.7 million, roughly flat from $292.6 million in the prior quarter.
  • The five-year high for Long-Term Deferred Tax was $420.0 million in Q1 2025, with the low at $98.0 million in Q2 2022.
  • The 5-year median for Long-Term Deferred Tax is $293.7 million (2026), against an average of $291.6 million.
  • The sharpest annual moves came in 2022 and 2023: Long-Term Deferred Tax plunged 38.98% in 2022, then jumped 134.29% in 2023.
  • Exelixis' Long-Term Deferred Tax stood at $231.1 million in 2022, then surged by 56.27% to $361.1 million in 2023, then dropped by 0.63% to $358.9 million in 2024, then rose by 16.64% to $418.6 million in 2025, then slipped by 29.83% to $293.7 million in 2026.
  • Business Quant data shows EXEL's Long-Term Deferred Tax at $293.7 million in Q2 2026, $292.6 million in Q1 2026, and $418.6 million in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Exelixis 14.81 Bn 13.97 Bn 608.03 Mn
Historic Data

Historic Data

Download Data
DateValue
Jul 3, 2026 294.21 Mn
Apr 3, 2026 293.73 Mn
Jan 2, 2026 292.58 Mn
Oct 3, 2025 418.58 Mn
Jul 4, 2025 419.24 Mn
Apr 4, 2025 419.05 Mn
Jan 3, 2025 420.03 Mn
Sep 27, 2024 358.87 Mn
Jun 28, 2024 361.56 Mn
Mar 29, 2024 361.58 Mn
Dec 29, 2023 361.15 Mn
Sep 29, 2023 230.99 Mn
Jun 30, 2023 231.12 Mn
Mar 31, 2023 229.60 Mn
Dec 30, 2022 231.11 Mn
Sep 30, 2022 116.42 Mn
Jul 1, 2022 113.96 Mn
Apr 1, 2022 98.00 Mn
Dec 31, 2021 111.66 Mn
Oct 1, 2021 125.30 Mn